Vinorelbine ditartrate 是一种抗有丝分裂剂,能够抑制 Hela 细胞的增殖,IC50值为 1.25 nM。
酒石酸长春瑞滨
jiǔ shí suān cháng chūn ruì bīn
更新时间:2024-04-16 11:33:26
- 常用名酒石酸长春瑞滨英文名vinorelbine L-tartrate
- CAS号125317-39-7分子量1079.106
- 密度1.36g/cm3沸点N/A
- 分子式C53H66N4O20熔点181-183°C
- MSDS闪点N/A
- 符号信号词
- 中文名酒石酸长春瑞滨
- 英文名vinorelbine L-tartrate
- 中文别名长春瑞宾双酒石酸盐 |重酒石酸长春瑞滨 |
- 英文别名methyl (2β,3β,4β,5α,12β,19α)-4-(acetyloxy)-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxybutanedioate) (salt) |aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt) |MFCD03613607 |methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxybutanedioate) (salt) |Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxysuccinate (1:2) |Vinorelbine Ditartarate |methyl (2β,3β,4β,5α,12β,19α)-4-(acetyloxy)-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-1 |Nor-5'-anhydrovinblastine ditartrate |Vinorelbine ditartrate salt |Eunades |Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, m ;ethyl ester, (2β,3β,4β,5α,12β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt) |Vinorelbine tartrate |-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxybutanedioate) (salt) |methyl (2β,3β,4β,5α,12β,19α)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxybutanedioate (1:2) |6-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxybutanedioate) (salt) |2,3-Dihydroxybutandisäure-methyl-(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-5-carboxylat(2:1) |aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, m |ethyl ester, (2β,3β,4β,5α,12β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt) |Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxysuccinate) (salt) |Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-me
 thoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxysuccinate (1:2) |3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine (R-(R*,R*))-2,3-dihydroxybutanedioate (1:2) (salt) |acide 2,3-dihydroxybutanedioïque - (3aR,4R,5S,5aR,10bR,13aR)-4-(acétyloxy)-3a-éthyl-9-[(12S,14R)-16-éthyl-12-(méthoxycarbonyl)-1,10-diazatétracyclo[12.3.1.0.0]octadéca-3(11),4,6,8,15-pentaén-12-yl]-5-hydroxy-8-méthoxy-6-méthyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate de méthyle (2:1) |methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy |Vinorelbine ditartrate |Methyl (3aR,4R,5S,5aR,10bR,13aR)-4-acetoxy-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxysuccinate) (salt) |Vinorelbine |Vinorelbine (ditartrate) |
- 描述Vinorelbine ditartrate 是一种抗有丝分裂剂,能够抑制 Hela 细胞的增殖,IC50值为 1.25 nM。
- 相关类别信号通路 >> 自噬 >> 自噬 信号通路 >> 细胞周期/DNA损伤 >> 微管/微管蛋白 信号通路 >> 细胞骨架 >> 微管/微管蛋白 研究领域 >> 癌症
- 体外研究长春瑞滨(0.5-5nM)在浓度为1.25nM时抑制细胞增殖50%(IC50)。浓度为8 nM的长春瑞滨时,没有细胞处于后期[1]。长春瑞滨时间依赖性地诱导雄激素依赖性(AD)和非依赖性(AI)前列腺癌细胞系中的p53和p21WAFI / CIP1表达。长春瑞滨以浓度依赖性方式刺激报告基因[2]。
- 体内研究长春瑞滨治疗后,第一次中性粒细胞过多发生在狗的第一次(4只狗),第二次(1)或第六次(1)长春瑞滨治疗后[3]。长春瑞滨在携带肿瘤的猫中每周耐受一次,MTD为11.5 mg / m2 [4]。
- 动物实验根据该研究的定义,将VRL1在0.9%NaCl中稀释至1.5mg / mL的浓度,并在5分钟内进行IV。预期的治疗间隔为7天,最多4次治疗。在每周接受4次剂量后,猫有资格每2周继续接受VRL治疗。
- 参考文献[1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32. [2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73. [3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9. [4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8.
- 密度1.36g/cm3
- 熔点181-183°C
- 分子式C53H66N4O20
- 分子量1079.106
- 精确质量1078.427002
- PSA363.99000
- LogP0.44920
- 外观性状白色至灰白色结晶粉末
- 折射率1.675
- 储存条件
密封、在2 ºC -8 ºC下保存
- 稳定性
如果遵照规格使用和储存则不会分解,未有已知危险反应
- 水溶解性H2O: 10 mg/mL
- 分子结构
1、摩尔折射率:无可用的
2、摩尔体积(cm3/mol):无可用的
3、等张比容(90.2K):无可用的
4、表面张力(dyne/cm):无可用的
5、介电常数:无可用的
6、极化率(10-24cm3):无可用的
7、单一同位素质量:1078.427041 Da
8、标称质量:1078 Da
9、平均质量:1079.1059 Da
- 计算化学
1、 疏水参数计算参考值(XlogP):
2、 氢键供体数量:10
3、 氢键受体数量:23
4、 可旋转化学键数量:16
5、 互变异构体数量:
6、 拓扑分子极性表面积(TPSA):364
7、 重原子数量:77
8、 表面电荷:0
9、 复杂度:1820
10、同位素原子数量:0
11、确定原子立构中心数量:11
12、不确定原子立构中心数量:1
13、确定化学键立构中心数量:0
14、不确定化学键立构中心数量:0
15、共价键单元数量:3
- 更多
1. 性状:白色粉末
2. 密度(g/mL,20℃):未确定
3. 相对蒸汽密度(g/mL,空气=1):未确定
4. 熔点(ºC):181-183
5. 沸点(ºC,常压):未确定
6. 沸点(ºC,KPa):未确定
7. 折射率:未确定
8. 闪点(ºC):未确定
9. 比旋光度(º):未确定
10. 自燃点或引燃温度(ºC):未确定
11. 蒸气压(Pa,20ºC):未确定
12. 饱和蒸气压(KPa,20ºC):未确定
13. 燃烧热(KJ/mol):未确定
14. 临界温度(ºC):未确定
15. 临界压力(KPa):未确定
16. 油水(辛醇/水)分配系数的对数值:未确定
17. 爆炸上限(%,V/V):未确定
18. 爆炸下限(%,V/V):未确定
19. 溶解性:水:10mg/ml
- 危害码 (欧洲)Xi:Irritant
- 风险声明 (欧洲)R43
- 安全声明 (欧洲)26-36
- 危险品运输编码NONH for all modes of transport
- WGK德国3
- 海关编码2942000000
酒石酸长春瑞滨 合成路线
共页
- 海关编码2942000000